Rikke

BioCryst reports fourth quarter and full year 2023 financial results and upcoming key milestones Biocryst Pharmaceuticals Inc today reported financial results for the fourth quarter and full year ended 31 December 2023, and provided a corporate update. Jon Stonehouse, President and Chief Executive Officer of BioCryst. “The impressive growth we are seeing with Orladeyo [...]

KalVista Pharmaceuticals presents additional phase-3 KONFIDENT data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting KalVista Pharmaceuticals today announced that it presented additional data on its phase 3 KONFIDENT trial for sebetralstat, including a more in-depth analysis of sebetralstat efficacy and safety at the 2024 American Academy of Allergy, Asthma [...]

KalVista Pharmaceuticals presents data on unmet needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting KalVista Pharmaceuticals today announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the 2024 American Academy [...]

BioCryst presents new real-world data showing rapid, substantial and sustained HAE attack rate reductions after beginning Orladeyo (berotralstat) treatment Biocryst Pharmaceuticals Inc today announced new analyses of real-world use of oral, once-daily Orladeyo (berotralstat) that showed patients who initiated Orladeyo experienced rapid, substantial and sustained reductions in attack rates through 18 months of treatment [...]

Intellia Therapeutics announces fourth quarter and full-year 2023 financial results and highlights recent company progress Intellia Therapeutics today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2023. Intellia President and Chief Executive Officer, John Leonard MD, said: “We’re off to a very strong start in 2024 as [...]

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting Pharvaris today announced the upcoming presentation of two posters at the American Academy of Allergy, Asthma, & Immunology (AAAAI) 2024 Annual Scientific Meeting, to be held in Washington DC from [...]

Astria Therapeutics to present at upcoming American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Astra Therapeutics today announced that it will present final STAR-0215 Phase 1a healthy subject data at the upcoming American Academy of Allergy, Asthma, & Immunology (AAAAI) Annual Meeting in Washington, D.C. on February 23, 2024 at 3:15pm Eastern [...]

BioCryst launches Orladeyo (berotralstat) in Italy BioCryst Pharmaceuticals Inc today announced that the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA), has finalized reimbursement and recommended Orladeyo (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Italy now [...]

KalVista Pharmaceuticals awarded UK innovation passport for sebetralstat KalVista Pharmaceuticals today announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Innovation Passport for sebetralstat, an investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE). The Innovation Passport is the first step in the UK’s Innovative [...]

KalVista Pharmaceuticals to present phase-3 sebetralstat data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting KalVista Pharmaceuticals today announced the acceptance of multiple abstracts at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Washington, DC from 23-26 February 2024. The following presentations will [...]